WO2015004634A3 - Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire - Google Patents

Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire Download PDF

Info

Publication number
WO2015004634A3
WO2015004634A3 PCT/IB2014/063019 IB2014063019W WO2015004634A3 WO 2015004634 A3 WO2015004634 A3 WO 2015004634A3 IB 2014063019 W IB2014063019 W IB 2014063019W WO 2015004634 A3 WO2015004634 A3 WO 2015004634A3
Authority
WO
WIPO (PCT)
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
PCT/IB2014/063019
Other languages
English (en)
Spanish (es)
Other versions
WO2015004634A2 (fr
Inventor
Jorge Fernando CANTÚ MEDELLIN
Original Assignee
More Pharma Corporation, S. De R.L. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015004634(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corporation, S. De R.L. De C.V. filed Critical More Pharma Corporation, S. De R.L. De C.V.
Priority to CU2016000002A priority Critical patent/CU24440B1/es
Priority to MX2015013911A priority patent/MX366118B/es
Publication of WO2015004634A2 publication Critical patent/WO2015004634A2/fr
Publication of WO2015004634A3 publication Critical patent/WO2015004634A3/fr
Priority to CR20160021A priority patent/CR20160021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une combinaison de paracétamol et de célécoxib qui dans des quantités spécifiques génèrent un potentialisateur analgésique contre la douleur de type inflammatoire. Plus particulièrement, l'invention concerne une combinaison synergique qui comprend entre 375 à 500 mg de paracétamol et entre 50 à 100 mg de célécoxib utile dans le traitement de la douleur inflammatoire des animaux et des êtres humains, ainsi que l'utilisation de ces principes actifs dans les quantités indiquées pour la préparation de combinaisons pharmaceutiques synergiques.
PCT/IB2014/063019 2013-07-11 2014-07-11 Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire WO2015004634A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU2016000002A CU24440B1 (es) 2013-07-11 2014-07-11 Composición farmacéutica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2015013911A MX366118B (es) 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
CR20160021A CR20160021A (es) 2013-07-11 2016-01-11 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB2013/055710 2013-07-11
PCT/IB2013/055710 WO2015004505A1 (fr) 2013-07-11 2013-07-11 Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire

Publications (2)

Publication Number Publication Date
WO2015004634A2 WO2015004634A2 (fr) 2015-01-15
WO2015004634A3 true WO2015004634A3 (fr) 2015-04-09

Family

ID=52279400

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2013/055710 WO2015004505A1 (fr) 2013-07-11 2013-07-11 Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire
PCT/IB2014/063019 WO2015004634A2 (fr) 2013-07-11 2014-07-11 Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/055710 WO2015004505A1 (fr) 2013-07-11 2013-07-11 Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire

Country Status (8)

Country Link
CL (1) CL2015003211A1 (fr)
CR (1) CR20160021A (fr)
CU (1) CU24440B1 (fr)
DO (1) DOP2016000008A (fr)
EC (1) ECSP16005679A (fr)
MX (1) MX366118B (fr)
PE (2) PE20170305A1 (fr)
WO (2) WO2015004505A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090517A1 (en) * 2002-02-19 2005-04-28 Norris Michael C. Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2006043025A1 (fr) * 2004-10-19 2006-04-27 Reckitt Benckiser Healthcare (Uk) Limited Compositions granulaires comprenant des granules de fusion solidifies d’un inhibiteur selectif de cox-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090517A1 (en) * 2002-02-19 2005-04-28 Norris Michael C. Pharmaceutical combinations of cox-2 inhibitors and opiates
WO2006043025A1 (fr) * 2004-10-19 2006-04-27 Reckitt Benckiser Healthcare (Uk) Limited Compositions granulaires comprenant des granules de fusion solidifies d’un inhibiteur selectif de cox-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATZ W A ET AL.: "Dilemmas in Chronic/Persistent Pain Management.", DISEASE-A-MONTH, vol. 56, no. 4, CHICAGO, IL , US, pages 233 - 250, XP026985412 *

Also Published As

Publication number Publication date
PE20170305A1 (es) 2017-04-21
WO2015004505A1 (fr) 2015-01-15
CL2015003211A1 (es) 2016-04-29
PE20160239A1 (es) 2016-05-13
WO2015004634A2 (fr) 2015-01-15
MX2015013911A (es) 2015-12-08
ECSP16005679A (es) 2017-08-31
CU24440B1 (es) 2019-09-04
CR20160021A (es) 2016-04-08
MX366118B (es) 2019-06-27
CU20160002A7 (es) 2016-06-29
DOP2016000008A (es) 2016-03-15

Similar Documents

Publication Publication Date Title
WO2015077503A8 (fr) Composés inhibiteurs de l'autotaxine
WO2015023976A3 (fr) Inhibiteurs sélectifs de la grp94 et leurs utilisations
MX2015004644A (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
WO2014205389A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
WO2013158680A3 (fr) Compositions et méthodes comprenant du célécoxib ou composés apparentés et du dextrométhorphane
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX365427B (es) Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
WO2015056094A3 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
WO2014153009A3 (fr) Agents mucolytiques thiosaccharidiques
WO2014107730A3 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
WO2015082590A3 (fr) Dérivés de bis-mmf
WO2015004634A3 (fr) Combinaison synergique de paracétamol/célécoxib pour le traitement de douleur inflammatoire
WO2013033602A3 (fr) Amides d'acide gras, compositions et procédés d'utilisation
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
IN2013MU03428A (fr)
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
AU2014353885A8 (en) Prevention and treatment of toxicosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14822222

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/013911

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015029461

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 000043-2016

Country of ref document: PE

Ref document number: CR2016-000021

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 16005863

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 14822222

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 002763-2016

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 112015029461

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151125